These limitations highlight the need for new approaches and novel targets, including hormone-sparing treatments and non-AR targeted therapies, to better address the varied clinical needs of patients with prostate cancer, particularly those with advanced prostate cancer or mCRPC. This evidence concerns the gene AR and prostate carcinoma.